This statistic shows the number of deaths due to stomach cancer in the United States from 1999 to 2021. The highest number of deaths within the given period due to stomach cancer was 12,711, reported in 1999.

This statistic shows the death rate of stomach cancer in the United States from 1999 to 2021. The maximum death rate in the given period was *** per 100,000 inhabitants in 1999. The minimum death rate stood at *** in 2021.

BackgroundGastric cancer (GC) is a significant public health concern in the USA, and its burden is on the rise.MethodsThis study utilized the latest data from the Global Burden of Disease (GBD) study. We provided descriptive statistics on the incidence, prevalence, mortality, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) of GC across the USA and states. By calculating percentage changes and average annual percentage changes (AAPC), along with conducting age-period-cohort analysis, we assessed the trends in the burden of GC. Decomposition analysis was then performed, followed by the application of an autoregressive integrated moving average (ARIMA) model to forecast changes in ASRs through 2036.ResultsFrom 1990 to 2021, the number of incidence and prevalence of GC in the USA increased, but age-standardized incidence rates (ASIR) trended downward (AAPC = -0.73, 95% confidence interval [CI]: -0.77 to -0.68) and age-standardized prevalence rates (ASPR) (AAPC = -0.99, 95% CI: -1.08 to -0.9) showed a decreasing trend. In addition, the number of deaths, DALYs, age-standardized mortality rates (ASMR) and age-standardized DALYs rates (ASDR) in GC showed a decreasing trend. The burden of GC was significantly higher in males compared to females. In addition, we found that the highest incidence and prevalence in females was in the age group of 75-79 years, whereas the highest incidence and prevalence in males was in the age group of 70-74 years.ConclusionGC is a major public health issue in the USA. Although ASIR, ASPR, ASMR, and ASDR for GC are decreasing, the number of incidence and prevalence of GC in the USA remains high, and the disease burden of GC in the USA remains high. Strengthening preventive interventions, particularly for men and patients over the age of 60, will be crucial in the future.

Counts and age-standardized rate of gastric adenocarcinoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

In 2019, stomach cancer was the type of cancer most commonly attributed to physical inactivity in the United States among both men and women aged 30 years and older. At that time, it was estimated that physical inactivity was attributable to around 18 percent of stomach cancer cases. This statistic shows the proportion of cancer cases in the United States attributable to physical inactivity in 2019.

The global Cancer Supportive Care Products market, valued at approximately $XX million in 2025, is projected to experience robust growth, driven by rising cancer incidence rates worldwide and an increasing geriatric population susceptible to the disease. The market's compound annual growth rate (CAGR) of 3.56% from 2025 to 2033 indicates a steady expansion, fueled by advancements in supportive care therapies and a growing awareness of the importance of improving the quality of life for cancer patients. Key drivers include the increasing demand for effective pain management solutions, the development of novel drugs with improved efficacy and safety profiles (such as targeted therapies minimizing side effects), and the expanding adoption of personalized medicine approaches tailored to individual patient needs. Market segmentation reveals a significant contribution from G-CSFs and ESAs, reflecting their crucial role in managing chemotherapy-induced neutropenia and anemia, respectively. However, challenges such as high treatment costs, stringent regulatory approvals, and potential side effects associated with certain supportive care medications represent significant restraints. Geographic analysis suggests that North America and Europe currently hold the largest market shares, owing to well-established healthcare infrastructure and higher healthcare spending. However, rapidly developing economies in Asia Pacific are expected to witness significant growth in the coming years, driven by rising cancer prevalence and increasing healthcare investments in these regions. The competitive landscape is characterized by a mix of established pharmaceutical giants and specialized biotechnology companies, each vying for market share through product innovation, strategic partnerships, and geographic expansion. The market's future trajectory will depend on several factors, including the successful development and launch of innovative supportive care therapies, the implementation of effective healthcare policies aimed at improving cancer care access and affordability, and ongoing research efforts focused on minimizing treatment-related side effects. Expansion into emerging markets and strategic collaborations between pharmaceutical companies and healthcare providers will also play a pivotal role in shaping the market's future. Growth in specific drug classes such as targeted antiemetics and novel pain management solutions will be closely monitored. Furthermore, the evolving regulatory landscape and pricing pressures will influence market dynamics, making proactive adaptation and strategic planning crucial for market players to maintain competitiveness and capitalize on growth opportunities. The increasing focus on patient-centric care and value-based healthcare will further propel the market's growth and influence the development and adoption of supportive care products. Recent developments include: In March 2022, Imugene, based in Australia, reported a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in patients with HER-2 positive gastric cancer., In March 2022, Novartis received United States Food and Drug Administration (FDA) approval for Pluvicto for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic). These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).. Key drivers for this market are: Large Number of Side-effects Associated with Cancer Treatment, Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure; Increasing Prevalence of Cancer. Potential restraints include: Large Number of Side-effects Associated with Cancer Treatment, Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure; Increasing Prevalence of Cancer. Notable trends are: NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Segment is Expected to Register High Growth Over the Forecast Period.

Gastric Cancer Tissue Segmentation Dataset

License: Apache-2.0

  Overview

This dataset is designed for tissue segmentation in gastric cancer cases. It consists of 100 Regions of Interest (ROIs) extracted from Whole Slide Images (WSIs) of 100 gastric cancer cases.

  Tissue Types

Six tissue types are annotated:

Tumor
Lymphoid stroma
Desmoplastic stroma
Smooth muscle
Necrosis
Others

  Data Source

The original WSIs are sourced from… See the full description on the dataset page: https://huggingface.co/datasets/zeyugao/GastricSemanticSegmentation.

Both disseminated tumor cells and noncancerous host cells contributed to cancer progression cooperatively in bone marrow. Bone marrow samples were obtained from 4 gastric cancer patients, and were separated into 3 fractions (CD45 positive, CD45 negative/EpCAM positive, and CD14 positive fractions) by the automagnetic-activated cell separation (AutoMACS) system using CD45, EpCAM, and CD14 microbeads (Miltenyi Biotec, Germany). microRNA expression profiles in each fractions were evaluated in order to identify candidate prognostic markers for gastric cancer patients. In 4 patients with gastric cancer, bone marrow samples (40 mL) were obtained from iliac bones. Nucleated cells were collected by gradient centrifugation using Ficoll-Paque PREMIUM (GE Healthcare Life Science, USA) and Leucosep (Greiner Bio-One, Germany) according to the manufacturer’s instructions. Next, we separated bone marrow cells into 3 fractions using MACS: CD45 positive (CD45+), CD45 negative/EpCAM positive (CD45-/EpCAM+), and CD14 positive (CD14+). microRNA expression levels of whole bone marrow cells and each fractions were measured by the miRCURY™ LNA array microarray (6th gen-hsa, mmu & rno#208402, Exiqon, Vedbaek, Denmark). The miRCURY™ LNA array microarray slides were scanned using the Agilent G2505C Microarray Scanner System (Agilent Technologies, Inc., USA) and the data analysis was carried out using the Feature Extraction 10.7.3.1 (Agilent Technologies, Inc., USA).

In 2019, it was estimated that 18 percent of stomach cancer deaths in the United States among adults aged 30 years and older could be attributed to physical inactivity. This statistic shows the proportion of cancer deaths in the United States attributable to physical inactivity in 2019.

The size of the Cancer Supportive Care Products Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.56% during the forecast period. Cancer supportive care products are a collection of various medications and treatments intended to reduce the side effects and symptoms involved in cancer treatment. Such products play a very vital role in enhancing the quality of the patient's life while suffering from cancer, helping them sustain the regimens of treatment more effectively. Supportive care products therefore deal with such issues as pain, nausea, fatigue, and infections-all those contributing to significant improvement in the patient's well-being and reduction in the burden of cancer. This market for cancer supportive care products would derive strength from such factors as an aging population, a rising incidence of cancer, advancing treatment methods of cancer, and raising awareness of the need for supportive care. The market can be categorized into various sections such as antiemetics, analgesics, anti-infectives, and hematopoietic growth factors. Recent developments include: In March 2022, Imugene, based in Australia, reported a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in patients with HER-2 positive gastric cancer., In March 2022, Novartis received United States Food and Drug Administration (FDA) approval for Pluvicto for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic). These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).. Key drivers for this market are: Large Number of Side-effects Associated with Cancer Treatment, Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure; Increasing Prevalence of Cancer. Potential restraints include: Advancements in Targated Therapy Drugs, Side Effects of Supportive Care Drugs; Stringent Regulatory Process. Notable trends are: NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Segment is Expected to Register High Growth Over the Forecast Period.

Snapshot img

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size 2024-2028

The her2 (human epidermal growth factor receptor 2) inhibitors market size is forecast to increase by USD 11.07 billion at a CAGR of 9.94% between 2023 and 2028.

The global human epidermal growth factor receptor 2 (HER2) inhibitors market has been propelled by continual development in R&D efforts. Treatment choices have been greatly increased, and patient outcomes have improved as a result of the discovery of more potent HER2 inhibitors through R&D initiatives. Notably, the landscape of HER2-positive breast and gastric cancer therapy has been revolutionized by more recent monoclonal antibodies and targeted medicines. Moreover, when combined with trastuzumab, the monoclonal antibody pertuzumab has demonstrated improved inhibition of HER2-positive tumor cell proliferation.
Additionally, continuing R&D projects concentrate on reducing adverse effects, enhancing drug delivery systems, and investigating novel medication combinations, assuring a constant influx of cutting-edge HER2 inhibitors. Such factors will increase the demand for HER2 inhibitors, thereby driving the growth of the market during the forecast period. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.

What will be the Size of the HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market During the Forecast Period?

Request Free Sample

The HER2 Inhibitors market encompasses a range of therapeutic agents designed to target the HER2 receptor proteins, which are overexpressed in various cancers, including Breast and Gastric cancer. These inhibitors comprise Tyrosine kinase inhibitors and Monoclonal antibodies. Tyrosine kinase inhibitors, such as Lapatinib and Neratinib, obstruct the HER2 receptor's tyrosine kinase activity, preventing cancer cell growth. Monoclonal antibodies, like Trastuzumab (Herceptin) and its biosimilars, bind to the HER2 receptor, inhibiting its function.
Additionally, Monotherapy and Combination therapy are employed in the treatment of HER2-positive cancers. Biotechnological advances have led to the development of alternative treatment options, such as Tucatinib and Pyrotinib. Precision oncology adoption and Biomarker testing are crucial in determining the most effective Anti HER2 drugs for individual patients. In the context of Ovarian Cancer, quantitative data suggests that HER2 Inhibitors demonstrate promising therapeutic potential. Patient advocacy and Precision medicine continue to drive the adoption of these drugs in the Healthcare sector.

How is this HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Industry segmented and which is the largest segment?

The HER2 (human epidermal growth factor receptor 2) inhibitors industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Monotherapy
  Combination therapy


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Product Insights

The monotherapy segment is estimated to witness significant growth during the forecast period.

The HER2 Inhibitors market encompasses tyrosine kinase inhibitors and monoclonal antibodies that target the HER2 receptor proteins in breast and gastric cancers. These anti-HER2 drugs have gained significant attention in the healthcare sector due to their efficacy in treating specific subtypes of breast cancer and lung cancer, such as HER2-positive carcinomas. Monotherapy, using these inhibitors, is a preferred treatment option for HER2-positive cancers, which respond largely to targeted therapies. Herceptin, a well-known HER2 inhibitor offered by Roche, accounts for approximately 20% of the 100 prescriptions for all breast cancers in the US. Biotechnological advances have led to the development of alternative treatment options, including Herceptin biosimilars, which offer cost-effective solutions for patients.

Additionally, precision oncology adoption and patient advocacy have further fueled the growth of the HER2 Inhibitors market. In the realm of precision medicine, biomarker testing plays a crucial role in identifying patients who would benefit from HER2-targeted therapies. Lapatinib, Neratinib, Tucatinib, and Pyrotinib are some of the notable HER2 Inhibitors that have shown promising results in clinical trials. The market outlook for HER2 Inhibitors is positive, with growth driven by increasing incidence rates of breast and gastric cancers, new business development, and invest

The DiCOM is a probabilistic state-transition cohort model that projects the population effect of nutrition policies on cancer outcomes. The model consists of 1) six health states: healthy without cancer, initial treatment with colorectal cancer, continuous care with colorectal cancer, initial treatment with stomach cancer, continuous care with stomach cancer, and dead (from cancer or other causes); 2) the annual likelihood of changes in health; and 3) the lifetime consequences of such changes on health outcomes and economic costs.14 Our model estimated health benefits (life years, quality-adjusted life-years (QALYs,) cancer incidence, and years living with cancer) and economic impact (e.g., policy implementation costs, healthcare costs, and productivity benefits).

Percent change in age-standardized and delay-adjusted incidence rates of gastric cancer from 2019 to 2020, by age, race and sex in the United States, using the November 2022 data submission.

Counts and age-standardized rate of gastrointestinal stromal tumor incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

Counts and age-standardized rate of carcinoid tumor incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

Counts and age-standardized rate of signet ring carcinoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

BackgroundColon cancer, esophageal cancer, and stomach cancer are the common causes of morbidity and mortality in China, Japan, the US., and India. The current study aims to assess and compare secular trends of the mortality of gastrointestinal cancers during the period, 1990–2017 in age-specific, time period, and birth cohort effects.MethodWe used the Joinpoint model to collect age-standardized mortality rates (ASMRs) for four countries. We designed an age-period-cohort (APC) analysis to estimate the independent effects on the mortality of three types of cancers.ResultThe Joinpoint model shows that in addition to the death rate of esophageal cancer in Japan, the ASMR of esophageal cancer and stomach cancer in other countries declined rapidly. The APC analysis presented a similar pattern of age effect between four countries for colon cancer and stomach cancer, which increased from 20 to 89 age groups. Differently, the period effect rapidly increased for esophageal cancer and stomach cancer in the US, and the period effect in China presented a declining volatility, showing its highest value in 2007. In future, highest mortality trends are likely to occur in China.ConclusionTherefore, the obvious increase in colon cancer recommended that earlier tactics must be performed to reduce mortality from specific causes from 2018 to 2027.

PurposeThe efficacy of tislelizumab plus chemotherapy in improving progression-free survival (PFS) and overall survival (OS) in unresectable gastric or gastroesophageal junction cancer (GC/GEJC) has recently been emphasized. This study compared the cost-effectiveness of tislelizumab plus chemotherapy versus placebo plus chemotherapy for the United States (US) and Chinese populations.MethodsUsing data from the RATIONALE-305 phase 3 trial, a Markov model was developed to analyze quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). The health state utilities and direct medical costs were obtained from the relevant literature and local cost databases. The model uncertainty was evaluated using sensitivity analyses.FindingsIn the base-case analysis, the addition of tislelizumab to chemotherapy yielded an ICER of $37,768.48 per QALY in China, slightly below the willingness-to-pay (WTP) threshold of $38,042.49 per QALY, showing marginal cost-effectiveness with an INHB of 0.05 QALYs and an INMB of $1,852.49. Subgroup analyses revealed ICERs of $23,853.52 for patients with a PD-L1 TAP score ≥ 5% (TAP ≥ 5%). In the US, the ICER was $502,786.22 per QALY in the intent-to-treat (ITT) and $321,395.28 per QALY in the TAP ≥ 5% subgroup, exceeding the US WTP threshold of $150,000.00.ImplicationsIn China, tislelizumab plus chemotherapy is a cost-effective first-line therapy for unresectable GC/GEJC in both ITT and TAP ≥ 5% subgroups. In the US, tislelizumab plus chemotherapy is not cost-effective.

Association of HBV infection status with all-cause mortality among US cancer survivors.

Additional supporting information. (PDF)